(NASDAQ:NMRA), NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits Neumora plans to provide a comprehensive M4 franchise update by mid-2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Neumora […]

(NASDAQ:SNDX), NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, 2025. In connection with the earnings release, Syndax's management will host a conference

(NASDAQ:IMTX), Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer (“CPO”) effective October 27, 2025. Ms. Krause brings more than 20 years of

(NasdaqGM:EDAP), EDAP to Participate in the UBS Global Healthcare Conference Company to Host 1×1 Investor Meetings on Monday, November 10th, 2025 AUSTIN, Texas, October 27, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, and Ken Mobeck, Chief Financial Officer,

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 GlobeNewswire October 27, 2025 Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal study Preliminary efficacy

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock GlobeNewswire October 27, 2025 SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of

First Northwest Bancorp Announces Third Quarter 2025 Results GlobeNewswire October 27, 2025 PORT ANGELES, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) — First Northwest Bancorp (Nasdaq: FNWB) (“First Northwest” or the “Company”), the holding company for First Fed Bank (“First Fed” or the “Bank”), today reported net income of $802,000 for the third quarter of 2025,

Currency Exchange International Announces Adoption of Shareholder Rights Plan GlobeNewswire October 27, 2025 TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Currency Exchange International, Corp. (the “Group” or “CXI“) (TSX: CXI; OTCQX: CURN), announced today that its board of directors (the “Board”) has unanimously approved the adoption of a “new generation” shareholder rights plan (the “Rights

Electra Advances Idaho Cobalt-Copper Assets as Cornerstone of America's Critical Minerals Independence Renewed exploration focus supports domestic mining strategy for Electra's fully financed North American cobalt refinery GlobeNewswire October 27, 2025 TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company“) has launched a new program

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 GlobeNewswire October 27, 2025 – All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial